LloydsPharmacy Clinical Homecare (LPCH) claims to have reached a milestone of reaching out to at least 100,000 patients across the UK in supporting them to undergo treatment in their own homes or communities.
LPCH offers the patients with an option to receive treatments for certain conditions closer to home. To meet the needs of the local communities, the LloydsPharmacy Clinical Homecare nurses, pharmacy teams and delivery drivers operate in high streets and homes across the country.
The multiple is also working in partnership with the NHS, pharmaceutical companies and private health insurers to suit patient needs and allows some treatments that do not need to be routinely managed in a hospital setting and can be carried out in the comfort of their home or local community.
LPCH also works in partnership with NHS consultants and nurses, medicines’ manufacturers, and patients and their carers to help people manage their conditions where they feel most comfortable.
Toby Anderson, CEO of McKesson UK, the parent company of LloydsPharmacy, said: “I am extremely proud that 100,000 patients are now receiving ongoing treatment closer to their home, supported by our LPCH nurses and support teams. LPCH helps patients with long-term and serious conditions to live more independent lives.
“More patients receiving their care through a clinical homecare pathway also means that local hospitals can concentrate on treating patients with acute and urgent conditions – something that is now more important than ever, as the NHS starts to recover from the Covid-19 pandemic. I want to thank all our colleagues in LPCH for their hard work, day in day out to support our patients.”
Over the last five years LPCH has seen significant growth in patient numbers, and now offers 28 different therapies and conditions, including cancer therapies, home parental nutrition, and enzyme replacement therapies.
LPCH also is investing in new innovations and partnerships to deliver the best patient care. It’s partnership with Careology, is the first of its kind and enables clinicians, oncology nurses and carers to remotely monitor patients using digital technology. The platform empowers patients by providing access to their own medical statistics, and is designed to significantly enhance patient experience, improving the quality of care provided and the health outcomes of patients.
In April 2021 LPCH also began administering a new treatment for breast cancer in its Healthcare Centres. The treatment, Phesgo, will improve patient experience significantly, reducing the time they need to spend undergoing treatment from 150 minutes to just 30 minutes.
Patients remain the highest priority for LPCH. In the last patient satisfaction survey 89% of patients said they were either ‘extremely likely’ or ‘likely’ to recommend LPCH to friends and family if they needed similar care or treatment – a true testament to the value patients place on this treatment option.
Nick Davis, operations director, LPCH, comments: “Giving patients the option to choose clinical homecare as part of their treatment pathway offers convenience and flexibility, allowing patients to live more independently.
“Our fantastic colleagues deliver high-quality care in communities and at patients’ homes every day, and it is a testament to their work that we have now reached the 100,000-patient milestone. At LPCH, we are always working to innovate and improve the experience for our patients and their families. As we care for an increasing number of patients, we will continue to offer the very best care, and ensure we have a positive impact on their lives.”